Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 1309-1317

  Zuo, Xiaoxiao ^a   Chen, Ling ^a   Liu, Lifeng ^a   Zhang, Zhe ^a   Zhang, Xiaojin ^a   Yu, Qing ^a   Feng, Lu ^a   Zhao, Xinhan ^a   Qin, Tianjie ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Antigens; Early stage breast cancer; Phage display technology; SEREX

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CA 15-3 ANTIGEN; GK2 PROTEIN; LGALS3 PROTEIN; MUCIN 1; PHB2 PROTEIN; UNCLASSIFIED DRUG; BIS(N-SUCCINYL-GLUTAMYLLYSIN)HEXAMETHYLENEDIAMINE; COMPLEMENTARY DNA; DIPEPTIDE; GALECTIN 3; GALECTIN-3, HUMAN; MUC1 PROTEIN, HUMAN; PEPTIDE LIBRARY; PROHIBITIN; REPRESSOR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA LIBRARY; EARLY CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHAGE DISPLAY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGY; AREA UNDER THE CURVE; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; EARLY CANCER DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETICS; PEPTIDE LIBRARY; PROCEDURES; REGRESSION ANALYSIS;

ANTIGENS, NEOPLASM; AREA UNDER CURVE; AUTOANTIBODIES; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIPEPTIDES; DNA, COMPLEMENTARY; EARLY DETECTION OF CANCER; FEMALE; GALECTIN 3; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; MUCIN-1; PEPTIDE LIBRARY; REGRESSION ANALYSIS; REPRESSOR PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84939637943     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3932-y     Document Type: Article

References (16)

1. Chourb S, Mackness BC, Farris LR, McDonald MJ. Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay. Health. 2011;3:1949–4998.
2. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. International journal of proteomics 2011, 2011.
3. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 2004;24:3221–4.
4. Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148.
5. Dong X, Yang M, Sun H, Lu J, Zheng Z, Li Z, et al. Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. Onco Targets Ther. 2013;6:273–9.
6. Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, et al. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. 2013;4:e753.
7. Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013;4:542–9.
8. Al-Salam S, Al-Salam M, Al AM. Galectin-3: a novel protein in cerebellar hemangioblastoma. Int J Clin Exp Pathol. 2013;6:853–61.
9. Righi A, Morandi L, Leonardi E, Farnedi A, Marucci G, Sisto A, et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol. 2013;44:2400–9.
10. Dawson H, Andre S, Karamitopoulou E, Zlobec I, Gabius HJ. The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Res. 2013;33:3053–9.
11. Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer. 2011;117:4375–80.
12. Lee MH, Lin L, Equilibrina I, Uchiyama S, Matsunaga S, Fukui K. ASURA (PHB2) is required for kinetochore assembly and subsequent chromosome congression. Acta Histochem Cytochem. 2011;44:247–58.
13. Sievers C, Billig G, Gottschalk K, Rudel T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS ONE. 2010;5:e12735.
14. Zhang Y, Wang Y, Xiang Y, Lee W, Zhang Y. Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation. J Thromb Haemost. 2012;10:411–8.
15. Cheng J, Gao F, Chen X, Wu J, Xing C, Lv Z, Xu W, Xie Q, Wu L, Ye S, Xie H, Zheng S, Zhou L. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy. MolCarcinog 2013.
16. Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007;15:77–83.